{
    "nct_id": "NCT06240598",
    "official_title": "Identification of Markers of Resistance During Frontline Therapy and Maintenance",
    "inclusion_criteria": "* Patients assigned female at birthâ‰¥ 18 years of age\n* Suspected or known stage III-IV epithelial ovarian cancer for which the patient has undergone, or is planned to undergo, attempted primary or interval debulking surgery\n* Homologous Recombination Deficiency testing should be planned to be completed prior to completion of initial platinum/taxane chemotherapy. HRD testing can be determined using :\n\n  * Confirmation of deleterious Somatic or Germline BRCA mutation\n  * CLIA certified test for HRD\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with the inability to swallow oral medications or impaired gastrointestinal absorption due to gastrectomy or drainage gastrostomy tube\n* Patients receiving standard of care or investigational protocol directed treatment are eligible for this study, with the exception of protocol directed treatment which would prohibit the SLL surgery from being performed",
    "miscellaneous_criteria": ""
}